[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345245":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":16,"locations":7,"responsibleParty":22,"collaborators":7,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":7,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":26,"sex":30,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":31,"phases":7,"briefSummary":32,"conditions":33,"keywords":36,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":46,"locationsCount":7},{"fullName":5,"class":6},"Kyowa Kirin Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":12},"BIOLOGICAL","Burosumab",[13,14,15],"UX023","Crysvita®","KRN23",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":21},"Development Division Project Management Department","CONTACT","609-919-1100","kkd.clintrial.82@kyowakirin.com",{"type":23,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100345245","expanded-access-to-burosumab-100345245",false,"NCT03775187","Expanded Access to Burosumab","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","ALL","EXPANDED_ACCESS","Individual patient expanded access requests may be considered for patients who have no other treatment options",[34,35],"X-linked Hypophosphatemia","Tumor-Induced Osteomalacia",[37,38,39,40],"Expanded Access","Compassionate Use","XLH","TIO","AVAILABLE","2025-02-28",{"date":44,"type":45},"2025-03-05","ACTUAL",{"name":5,"class":6}]